Most CML-CP patients quickly achieve CCyR with imatinib treatment, and their subsequent leukemic burden is only accurately reflected by the BCR-ABL transcript levels as detected by RQ-PCR. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.